JP2021525768A5 - - Google Patents
Info
- Publication number
- JP2021525768A5 JP2021525768A5 JP2020567029A JP2020567029A JP2021525768A5 JP 2021525768 A5 JP2021525768 A5 JP 2021525768A5 JP 2020567029 A JP2020567029 A JP 2020567029A JP 2020567029 A JP2020567029 A JP 2020567029A JP 2021525768 A5 JP2021525768 A5 JP 2021525768A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- tumor
- prinabulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679619P | 2018-06-01 | 2018-06-01 | |
| US62/679,619 | 2018-06-01 | ||
| PCT/US2019/034726 WO2019232257A1 (en) | 2018-06-01 | 2019-05-30 | Composition and method of treating cancer associated with egfr mutation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525768A JP2021525768A (ja) | 2021-09-27 |
| JP2021525768A5 true JP2021525768A5 (enExample) | 2022-06-06 |
| JP7500438B2 JP7500438B2 (ja) | 2024-06-17 |
Family
ID=68696755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567029A Active JP7500438B2 (ja) | 2018-06-01 | 2019-05-30 | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210161888A1 (enExample) |
| EP (1) | EP3801524B1 (enExample) |
| JP (1) | JP7500438B2 (enExample) |
| KR (1) | KR102790127B1 (enExample) |
| CN (1) | CN112543636B (enExample) |
| AU (1) | AU2019278886B2 (enExample) |
| CA (1) | CA3101612A1 (enExample) |
| DK (1) | DK3801524T3 (enExample) |
| ES (1) | ES3060133T3 (enExample) |
| MX (1) | MX420412B (enExample) |
| WO (1) | WO2019232257A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202008673WA (en) | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| JP2019511565A (ja) | 2016-02-08 | 2019-04-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | ツカレゾールまたはそのアナログを含む組成物 |
| AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20240110997A (ko) | 2017-02-01 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| EP3743074A4 (en) | 2018-01-24 | 2021-12-15 | Beyondspring Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| KR20240082379A (ko) * | 2021-10-03 | 2024-06-10 | 시스트이뮨, 인코포레이티드 | 암 치료 방법 및 이의 약제학적 조성물 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| KR20260019493A (ko) * | 2023-06-02 | 2026-02-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 종양 병용 요법 및 사용 방법 |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60316688T2 (de) * | 2002-08-02 | 2008-07-17 | Nereus Pharmaceuticals, Inc., San Diego | Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| CA2939165A1 (en) * | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
| LT2958943T (lt) * | 2013-02-20 | 2020-01-27 | The Trustees Of The University Of Pennsylvania | Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių |
| KR20240110996A (ko) * | 2015-02-12 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 면역 관문 저해제와 조합한 플리나불린의 용도 |
| SG10202008673WA (en) * | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| NZ778329A (en) * | 2017-03-13 | 2026-03-27 | Beyondspring Pharmaceuticals Inc | Compositions of plinabulin and use thereof |
-
2019
- 2019-05-30 JP JP2020567029A patent/JP7500438B2/ja active Active
- 2019-05-30 WO PCT/US2019/034726 patent/WO2019232257A1/en not_active Ceased
- 2019-05-30 EP EP19810149.5A patent/EP3801524B1/en active Active
- 2019-05-30 US US17/059,694 patent/US20210161888A1/en not_active Abandoned
- 2019-05-30 KR KR1020207036949A patent/KR102790127B1/ko active Active
- 2019-05-30 CA CA3101612A patent/CA3101612A1/en active Pending
- 2019-05-30 MX MX2020012799A patent/MX420412B/es unknown
- 2019-05-30 ES ES19810149T patent/ES3060133T3/es active Active
- 2019-05-30 AU AU2019278886A patent/AU2019278886B2/en active Active
- 2019-05-30 DK DK19810149.5T patent/DK3801524T3/da active
- 2019-05-30 CN CN201980050963.3A patent/CN112543636B/zh active Active
-
2025
- 2025-05-23 US US19/217,307 patent/US20250375440A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101678029B (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| US20080221138A1 (en) | Method of using SAHA and Erlotinib for treating cancer | |
| US20230398119A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| US20090247549A1 (en) | Methods of using saha and bortezomib for treating cancer | |
| JP2019521087A5 (enExample) | ||
| EP2799070B1 (en) | Effect potentiator for antitumor agents | |
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| EP3290038A1 (en) | Agent for alleviating adverse reaction to antitumor drug | |
| HRP20151444T4 (hr) | Sredstva za liječenje i postupci liječenja dlbcl | |
| US20210346383A1 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| US20210023025A1 (en) | Therapeutic agent for cancer | |
| EP3042669B1 (en) | Antitumor agent and antitumor effect enhancer | |
| US9682082B2 (en) | Combinations of AKT and MEK inhibitor compounds, and methods of use | |
| JP2021525768A (ja) | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 | |
| JP2022500479A5 (enExample) | ||
| RS64778B1 (sr) | Lečenje raka | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022502399A5 (enExample) | ||
| JP2020536068A5 (enExample) | ||
| US20090105329A1 (en) | Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies | |
| JP2022531980A5 (enExample) | ||
| JP6973456B2 (ja) | 癌化学療法時の副作用軽減剤 | |
| RU2020140303A (ru) | Композиция и способ для лечения рака, связанного с мутацией egfr | |
| WO2019220375A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| Opyrchal et al. | Aurora kinase inhibitors in breast cancer treatment |